In RRMS, the early course of the disease is characterised by intermittent relapses, and partial or complete recovery of function between exacerbations. The occurrence of relapses is a key measure of ...

Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple ...

Over the past 35 years, interferons have been explored in various formulations for the management of Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), such as essential ...